Novo Nordisk (NYSE: NVO) is moving to broaden its investment narrative beyond obesity and diabetes, with CEO Mike Doustdar outlining an ambitious vision for the company’s blockbuster drug portfolio.
Speaking Sunday at the American Diabetes Association conference in New Orleans, Doustdar said Novo must stay obsessed with what patients want as it explores new therapeutic frontiers.
The CEO pointed to research suggesting semaglutide, the active ingredient in Ozempic and Wegovy, may protect vital organs including the heart, liver and kidneys before patients have lost significant weight.
Doustdar said Novo is increasingly asking its scientists to study what other diseases future GLP-1 drugs could possibly address, suggesting weight reduction may one day become, in his words, “just an appendix of a different purpose.”
Novo researchers also presented data showing semaglutide reduced the biological age of the heart and kidneys using experimental protein-based aging clocks, with effects partly independent of weight loss and linked to lower mortality risk.
Scientists cautioned, however, that the analysis does not prove the drug actually slows the aging process itself, leaving the longevity narrative as a compelling but still early-stage proposition.
When asked whether Novo would consider expanding into areas such as skincare, hair loss and other appearance-related conditions, Doustdar answered simply “Yes,” a response that could signal a broader strategic reset for the company.
The comments arrive at a difficult moment for the Danish drugmaker, whose shares fell as much as 3.2% on the day, extending their year-to-date decline to approximately 15%.
Some investors have grown increasingly concerned that Novo is too concentrated in obesity and diabetes, which still account for more than 90% of its revenue, particularly as generic competition intensifies.
Rival Eli Lilly (NYSE: LLY), whose shares rose 2.60% on the same day, presented trial data showing its next-generation drug retatrutide helped patients lose as much as 28% of their body weight after 80 weeks of treatment.
By comparison, Novo’s own CagriSema has demonstrated more modest weight-loss results, fueling investor anxiety about the company’s long-term competitiveness in the high-stakes obesity market.
Lilly’s gains stand in stark contrast to Novo’s recent struggles, with the competitive gap between the two GLP-1 giants appearing to widen heading into the second half of 2026.
Doustdar’s pivot toward longevity research and aesthetic medicine appears designed to reassure investors that Novo’s scientific platform has meaningful room to grow beyond its current revenue base.
Whether the market will reward that vision depends heavily on whether Novo can translate its early organ-protection data into clinically validated, commercially viable treatments in the years ahead.
